Alx Oncology Holdings Inc (ALXO) - News Archive

ALX Oncology Advances Cancer Therapeutics: Key Updates on Evorpacept from Major Clinical Trials SOUTH SAN FRANCISCO, Calif. In a promising development for oncology, ALX Oncology Holdings Inc. (Nasdaq: ALXO) has announce...

: In recent months, ALX Oncology has reported significant advancements in its investigational CD47-blocker, evorpacept. These findings, spanning multiple clinical trials, hint at a transformative potential in the treatm...

In an era where precision medicine is at the forefront of oncological research, ALX Oncology Holdings Inc. has taken a significant stride with its latest findings set to be presented at the highly anticipated San Antoni...

In a promising development for multiple myeloma treatment, ALX Oncology has announced the dosing of the first patients in its UMBRELLA study, a randomized Phase 1/2 clinical trial evaluating the efficacy of Evorpacept,...

In a recent announcement, ALX Oncology Holdings Inc. revealed positive topline data from its ASPEN-06 Phase 2 trial, showcasing the potential of Evorpacept in enhancing tumor response in HER2-positive gastric cancer. Th...

: Recent clinical trial data from ALX Oncology Holdings Inc. has illuminated the potential of evorpacept, a next-generation CD47 blocker, in treating various forms of cancer. This article outlines the findings from thre...

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerSOUTH SAN FRANCISCO, Calif., June 02, 2024 - ALX Oncol...

ALX Oncology Holdings Inc., a prominent immuno-oncology firm with specialization in the development of therapies to suppress the CD47 immune checkpoint pathway, has recently embarked on a Phase 2 investigator-sponsored...

:This article aims to assess the clinical data reported by ALX Oncology regarding the use of evorpacept in combination with standard-of-care treatment in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma...

ALX Oncology Holdings Inc s Evorpacept, a novel therapeutic candidate for the treatment of cancer, has achieved significant progress with the acceptance of two clinical abstracts for presentation at the upcoming AACR An...

ALX Oncology Holdings Inc., a leading immuno-oncology company aiming to combat cancer by blocking the CD47 immune checkpoint pathway, recently revealed the pricing details of its highly anticipated underwritten public o...